A groundbreaking study reveals that the shingles vaccine may significantly reduce the risk of developing dementia, sparking new conversations about prevention strategies.
The shingles vaccine, known as the recombinant zoster vaccinehas emerged as a potential ally in the fight against dementia. A recent study involving more than 500,000 participants has uncovered a striking correlation: those who received the vaccine were 24% less likely to develop dementia compared to those who did not.
This finding adds to a growing body of evidence suggesting that the shingles vaccine may offer broader health benefits beyond its primary purpose. With over one million Britons currently living with dementia, this research offers a glimmer of hope in the quest for preventive measures against this devastating condition.
Key Findings from the Study
The study, published in the Annals of Internal Medicinefollowed participants for four years. The results showed that vaccinated individuals had a 19% chance of developing dementia, compared to 24% in the unvaccinated group. The average age of participants was 79, with nearly two-thirds being women—demographics that are particularly vulnerable to dementia.
Kaleen Hayesassociate director of pharmacoepidemiology at the Brown University School of Public Healthled the research. She noted, ‘We don’t know with certainty why the risk of dementia is lower with shingles vaccination, but we have a lot of ideas.’ One prominent theory suggests that the vaccine may prevent neuroinflammationa condition linked to both stroke and dementia.
Theories Behind the Connection
Experts believe that contracting shingles, a viral infection causing painful rashes and nerve pain, could increase the risk of developing dementia. The vaccine might prevent complications by activating the immune system and halting a pathway of inflammation that increases dementia risk.
Barak Gasterdirector of cognition in primary care at the University of Washingtonwelcomed the findings. He now includes this information in his recommendations: ‘Shingles is probably the most painful rash imaginable, and you’re lucky if it lasts just a few weeks and goes away. And then I add that there is some evidence that it may help protect your brain.’
However, not all experts are convinced. David Reubenprofessor of geriatrics at the David Geffen School of Medicineadvises caution. ‘The takeaway from this research is ‘stay tuned,’ he said. ‘I tell patients, ‘yes, there is some evidence supporting this, but it’s very early.’ I wouldn’t change my practice over this, but it’s interesting.’
Implications for the UK
Though the research was conducted in the US, the findings could have significant implications for the UK, where the uptake of the free shingles vaccine is notably low. The National Health Service (NHS) offers the jab to individuals aged 65 to 79 and those over 18 with vulnerable immune systems. However, in February, officials at the UK Health Security Agency (UKHSA) revealed that less than half of eligible over 65s had received their jab within the first year of being offered it. For those over 70, the uptake stands at just 53.1%.
Researchers hope to launch a large-scale clinical trial in the UK to further investigate whether the shingles vaccine can help protect against dementia. The newest study was observational, meaning the researchers cannot prove that the vaccine directly caused the reduction in dementia risk. However, the findings add to a growing body of evidence suggesting the shingles jab may help protect against the disease.
Last October, researchers from Case Western Reserve University reported that the vaccine was associated with a significantly lower risk of dementia in adults aged 50 and over. The study found the jab was linked to a 50% reduction in the risk of vascular dementia and a 25% lower risk of heart attack or stroke. Previous research has also suggested the vaccine may offer broader cardiovascular benefits.
Shingles, also known as herpes zoster, is caused by the reactivation of the chickenpox virus, which can remain dormant in the body for decades before reawakening. Around one in three people globally will develop shingles at some point in their life. This new research highlights the potential for the shingles vaccine to play a crucial role in preventing not just shingles but also other serious health conditions.
Live now
Upcoming matches
Netherlands
Sweden
Germany
Ivory Coast
Ecuador
Curaçao
Tunisia
JapanResults
Turkey
Paraguay
Brazil
Haiti
Scotland
Morocco
USA
Australia